| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/02/2006 | US20060025464 Benzimidazole derivatives as therapeutic agents |
| 02/02/2006 | US20060025452 Method of treating demyelinating diseases or conditions |
| 02/02/2006 | US20060025451 Novel pyrazole compounds as transforming growth factor (TGF) inhibitors |
| 02/02/2006 | US20060025432 N-[2-[(3-Chloro-2-fluorobenzyl)thio]-6-[(2-hydroxy-1-methylethyl)amino]-4-pyrimidinyl]- 4-morpholinesulfonamide; asthma, antiallergens; rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis |
| 02/02/2006 | US20060025428 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/02/2006 | US20060025426 controlling signal transduction; anticancer agents; angiogenesis inhibitors; vision defects; cardiovascular disorders; antidiabetic agents; antiischemic agents; antiinflamamtory agents |
| 02/02/2006 | US20060025423 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/02/2006 | US20060025413 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 02/02/2006 | US20060025411 Methods for treating diseases or conditions using dihydropteridinone compounds |
| 02/02/2006 | US20060025403 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/02/2006 | US20060025396 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 02/02/2006 | US20060025374 Novel oligoribonucleotide derivatives for specific inhibition of gene expression |
| 02/02/2006 | US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 02/02/2006 | US20060025360 Human cervical cancer protooncogene and protein encoded therein |
| 02/02/2006 | US20060024820 Chromosome-based platforms |
| 02/02/2006 | US20060024792 G-protein coupled receptors |
| 02/02/2006 | US20060024785 Having mutations in the Kinase domain region (KDR) and/or the FMS-like Tyrosine-Kinase region (FLT-1), said variants exhibiting modified binding characteristics at said regions compared with native VEGF; stimulates vasculogenesis or angiogenesis; wound healing |
| 02/02/2006 | US20060024754 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 02/02/2006 | US20060024664 Characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin |
| 02/02/2006 | US20060024659 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 02/02/2006 | US20060024334 Immunotherapeutic methods and systems |
| 02/02/2006 | US20060024318 Vaccination with immuno-isolated cells producing an immunomodulator |
| 02/02/2006 | US20060024316 Prostatic cancer vaccine |
| 02/02/2006 | US20060024299 Human osteoclast derived cathepsin |
| 02/02/2006 | US20060024293 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 02/02/2006 | US20060024290 prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics |
| 02/02/2006 | US20060024279 Retroviral vectors |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | US20060024233 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 02/02/2006 | US20060024232 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
| 02/02/2006 | DE19856463B4 Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren Retroviral pseudotyped with LCMV hybrid vectors |
| 02/02/2006 | DE102004034623A1 Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel New 6-formyl-tetrahydropteridines, processes for their preparation and their use as medicaments |
| 02/02/2006 | DE102004033670A1 Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel New Pyridodihydropyrazinone, process for their preparation and their use as medicaments |
| 02/02/2006 | CA2587019A1 Combination anticancer therapy and pharmaceutical compositions therefore |
| 02/02/2006 | CA2575356A1 Use of llt1 and/or cd161 for modulating the activity of cells of the immune system |
| 02/02/2006 | CA2575272A1 Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies |
| 02/02/2006 | CA2574594A1 Imidazopyrazine as tyrosine kinase inhibitors |
| 02/02/2006 | CA2574564A1 Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| 02/02/2006 | CA2574313A1 Inhibitors of hsp90 |
| 02/02/2006 | CA2574139A1 Inhibitors of hsp90 |
| 02/02/2006 | CA2573949A1 Epothilone combinations |
| 02/02/2006 | CA2573538A1 Inhibitors of vegf receptor and hgf receptor signaling |
| 02/02/2006 | CA2573018A1 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 02/02/2006 | CA2572971A1 Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase |
| 02/02/2006 | CA2572833A1 Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| 02/02/2006 | CA2571424A1 Bisarylurea derivatives useful for inhibiting chk1 |
| 02/02/2006 | CA2570729A1 Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| 02/01/2006 | EP1621635A2 Self-assembling recombinant HP16 papillomavirus capsid proteins |
| 02/01/2006 | EP1621622A1 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof |
| 02/01/2006 | EP1621554A1 Immunoglobulins devoid of light chains |
| 02/01/2006 | EP1621553A1 Antibodies that inhibit transport activity of peptide transporters |
| 02/01/2006 | EP1621551A1 Use of LLT1 and/or CD161 for modulating the activity of cells of the immune system |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621540A1 Nitrogen-containing heterocyclic compounds and use thereof |
| 02/01/2006 | EP1621533A1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents |
| 02/01/2006 | EP1621206A1 Chimeric cytokines and uses thereof |
| 02/01/2006 | EP1621191A1 Treatment of inflammatory diseases by RXR Antagonists |
| 02/01/2006 | EP1621077A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 02/01/2006 | EP1620411A2 Inhibitors of akt activity |
| 02/01/2006 | EP1620409A1 Quinoxalin-3-one derivatives as orexin receptor antagonists |
| 02/01/2006 | EP1620397A1 Hydroxamic acids useful in the treatment of hyper-proliferative disorders |
| 02/01/2006 | EP1620381A1 Hydroanthracene based compounds as anticancer agents |
| 02/01/2006 | EP1620135A1 In vivo imaging using peptide derivatives |
| 02/01/2006 | EP1620121A2 The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells |
| 02/01/2006 | EP1620117A2 Improved antitumoral treatments |
| 02/01/2006 | EP1620115A1 Composition and method for supporting cancer treatments |
| 02/01/2006 | EP1620104A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use |
| 02/01/2006 | EP1620099A1 Use of irinotecan for treatment of resistant breast cancer |
| 02/01/2006 | EP1620094A2 Novel chemical compounds |
| 02/01/2006 | EP1620092A2 Compounds, compositions, and methods |
| 02/01/2006 | EP1620090A1 Pyrazole compounds as hsp90 inhibitors for the treatment of cancer |
| 02/01/2006 | EP1620056A2 Tumor cytotoxicity induced by modulators of the cxcr4 receptor |
| 02/01/2006 | EP1509202A4 Novel high viscosity embolizing compositions comprising prepolymers |
| 02/01/2006 | EP1463707A4 A group of novel anti-cancer compounds with specific structure |
| 02/01/2006 | EP1436293B1 Polycyclic compounds having anti-tumor activity |
| 02/01/2006 | EP1430144A4 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 02/01/2006 | EP1410013A4 Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| 02/01/2006 | EP1235812B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 02/01/2006 | EP1200479B1 Multiple cytokine-antibody complexes |
| 02/01/2006 | EP1169336B1 Ent-steroids as selectively active estrogens |
| 02/01/2006 | EP1146894B1 Uses of thank protein, a tnf homologue, to inhibit growth of tumour cells |
| 02/01/2006 | EP1101819B1 GENE Any-RF, DORMANCY REGULATORY SUBSTANCE, PROCESS FOR PRODUCING THE SAME AND CELL REGULATOR FOR VITAL CELLS |
| 02/01/2006 | EP1064402B1 Antisense modulation of lfa-3 |
| 02/01/2006 | EP0956040B1 Stimulation of host defense mechanisms against viral challenges |
| 02/01/2006 | EP0907736B1 Cc-type chemokines |
| 02/01/2006 | EP0906119B1 Stimulation of host defense mechanisms against cancer |
| 02/01/2006 | EP0898478B1 Stimulation of host defence mechanisms against tumors |
| 02/01/2006 | CN1729291A Exon 1beta of PDGF receptor alpha gene and utilization thereof |
| 02/01/2006 | CN1729192A Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| 02/01/2006 | CN1729190A Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics |
| 02/01/2006 | CN1729189A Pyridino [2, 3-D] pyrimidine derivatives as selective KDR and FGFR inhibitors |
| 02/01/2006 | CN1729019A Wild-type RAD as a cancer therapeutic agent |
| 02/01/2006 | CN1729012A Method and composition for preventing and treating solid tumors |
| 02/01/2006 | CN1729002A Exemestane as chemopreventing agent |
| 02/01/2006 | CN1729001A 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
| 02/01/2006 | CN1728991A Combination therapy for the treatment of cancer |
| 02/01/2006 | CN1727477A siRNA for restraining expression and proliferation of tumor and leukaemia cell VEGE and application |
| 02/01/2006 | CN1727362A Preparation and application of vaccine for curing tumor in positive carcino-embryonic antigen |
| 02/01/2006 | CN1727351A Method for preparing compound of vegetative phosphatidylinositol in high purity |
| 02/01/2006 | CN1727340A Temozolomide 8-carboxylic ester, and combination |